Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Hematology and Medical Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Cancer Immunol Immunother. 2021 Oct;70(10):2961-2969. doi: 10.1007/s00262-021-02889-5. Epub 2021 Mar 15.
For many decades, selenium (Se) has been known as a potential anti-cancer agent that can also improve the function of immune cells in a variety of solid tumors. However, there is no report on the role of Se on CD4 T cell subsets like CD4CD25FOXP3 regulatory T cells (Tregs) in lymphoma patients. In this randomized clinical trial, we investigated the effect of 3-month Se consumption on the frequency of CD4CD25FOXP3 Tregs and the expression of immune checkpoint receptors in thirty-two non-Hodgkin lymphoma (NHL) patients (16 patients with Se (Se+) and 16 without Se (Se-) consumption) with diffuse large B-cell lymphoma (DLBCL) subtype at stable remission. The change in the frequency of Tregs and expression of immune checkpoint receptors including CTLA-4, LAG-3, TIM-3, and PD-L1 genes were evaluated after 3 months in both groups using flow cytometry and SYBR Green Real-time PCR method, respectively. The results showed that the frequency of CD4CD25FOXP3 Tregs and expression of immune checkpoint receptors did not significantly change after 3-month Se consumption in DLBCL patients. However, alteration in the frequency of CD4CD25FOXP3 Treg subsets was positively correlated with change in CTLA-4, LAG-3, and TIM-3 expression in the Se+ group. Three-month Se supplementation did not prevent relapse in Se+ group. Taken together, Se supplementation alone did not affect the frequency of CD4CD25FOXP3 Tregs, expression of checkpoint receptors, and prevention of relapse in DLBCL patients at stable remission phase but might influence the functional properties of other Treg subsets like CD4CD25FOXP3 Tregs.
几十年来，硒（Se）一直被认为是一种潜在的抗癌剂，它还可以改善各种实体肿瘤中免疫细胞的功能。然而，目前尚无关于 Se 对淋巴瘤患者 CD4 T 细胞亚群（如 CD4CD25FOXP3 调节性 T 细胞[Tregs]）的作用的报道。在这项随机临床试验中，我们研究了 3 个月的 Se 消耗对 32 例弥漫性大 B 细胞淋巴瘤（DLBCL）亚型稳定缓解的非霍奇金淋巴瘤（NHL）患者（16 例 Se（Se+）和 16 例不消耗 Se（Se-））中 CD4CD25FOXP3 Tregs 的频率和免疫检查点受体表达的影响。分别采用流式细胞术和 SYBR Green 实时 PCR 方法，在两组中分别评估 3 个月后 Tregs 频率和 CTLA-4、LAG-3、TIM-3 和 PD-L1 基因表达的免疫检查点受体的变化。结果表明，在 DLBCL 患者中，3 个月的 Se 消耗后，CD4CD25FOXP3 Tregs 的频率和免疫检查点受体的表达并没有显著变化。然而，CD4CD25FOXP3 Treg 亚群频率的改变与 Se+组中 CTLA-4、LAG-3 和 TIM-3 表达的改变呈正相关。3 个月的 Se 补充并不能预防 Se+组的复发。综上所述，单独补充 Se 并不能影响稳定缓解期 DLBCL 患者 CD4CD25FOXP3 Tregs 的频率、检查点受体的表达和复发的预防，但可能会影响其他 Treg 亚群（如 CD4CD25FOXP3 Tregs）的功能特性。
